IKT

Over the past six months, Inhibikase Therapeutics announced a $100 million and a $115 million public offering of common stock and pre-funded warrants. The company announced its full-year 2025 financial results, including a net loss of $48.3 million. Inducement grants were announced under Nasdaq Listing Rule 5635(c)(4). The first patient was enrolled in the IMPROVE-PAH Global Phase 3 Study of IKT-001. Bank of America and LADENBURG THALM/SH SH initiated coverage with "buy" ratings, while Weiss Ratings reissued a "sell (d-)" rating, and Lifesci Capital upgraded the company to a "strong-buy" rating. The stock's 52-week range has been between $1.33 and $2.27.